Received Apr 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | — | LA |
redness at injection site, slight swelling and warm to the touch; redness at injection site, slight swelling and warm to the touch; redness at injection site, slight swelling and warm to the touch; This is a spontaneous report received from a Consumer or other non HCP. A 19-year-old female patient (not pregnant) received BNT162b2 omicron (kp.2) (COMIRNATY (2024-2025 FORMULA)), on 26Apr2025 as dose 1, single (Batch/Lot number: unknown) at the age of 19 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "dysautonomia" (unspecified if ongoing); "nut allergy" (unspecified if ongoing); "crohn" (unspecified if ongoing); "EOE" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: VACCINATION SITE ERYTHEMA (non-serious), VACCINATION SITE SWELLING (non-serious), VACCINATION SITE WARMTH (non-serious) all with onset 27Apr2025 at 10:00, outcome "unknown" and all described as "redness at injection site, slight swelling and warm to the touch". Therapeutic measures were not taken as a result of vaccination site erythema, vaccination site swelling, vaccination site warmth. The information on the batch/lot number for BNT162b2 omicron (kp.2) will be requested and submitted if and when received.
Medical History/Concurrent Conditions: Allergy to nuts; Crohn's; Dysautonomia; Eosinophilic oesophagitis